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Abstract
Background: The development of techniques for sequencing the messenger RNA (RNA-Seq) enables it to study
the biological mechanisms such as alternative splicing and gene expression regulation more deeply and accurately.
Most existing methods employ RNA-Seq to quantify the expression levels of already annotated isoforms from the
reference genome. However, the current reference genome is very incomplete due to the complexity of the
transcriptome which hiders the comprehensive investigation of transcriptome using RNA-Seq. Novel study on
isoform inference and estimation purely from RNA-Seq without annotation information is desirable.
Results: A Nonnegativity and Sparsity constrained Maximum APosteriori (NSMAP) model has been proposed to
estimate the expression levels of isoforms from RNA-Seq data without the annotation information. In contrast to
previous methods, NSMAP performs identification of the structures of expressed isoforms and estimation of the
expression levels of those expressed isoforms simultaneously, which enables better identification of isoforms. In the
simulations parameterized by two real RNA-Seq data sets, more than 77% expressed isoforms are correctly
identified and quantified. Then, we apply NSMAP on two RNA-Seq data sets of myelodysplastic syndromes (MDS)
samples and one normal sample in order to identify differentially expressed known and novel isoforms in MDS
disease.
Conclusions: NSMAP provides a good strategy to identify and quantify novel isoforms without the knowledge of
annotated reference genome which can further realize the potential of RNA-Seq technique in transcriptome
analysis. NSMAP package is freely available at https://sites.google.com/site/nsmapforrnaseq.
Background
More than 90% of human genes [1,2] are estimated to
be alternatively spliced which leads a single gene to pro-
duce multiple proteins with distinct functions and is
implicated in many diseases including cancer [3]. In
recent years, there is an increasing interest in the use of
alternative splicing in developing diagnostic tools and in
identifying new therapeutic targets [4]. Microarrays have
been widely used to analyze alternative isoforms by
combining exon arrays and exon junction arrays to
quantify isoform level expression indexes [5,6]. However,
array based techniques are encountering several funda-
mental problems such as cross hybridization and weak
signals in junction probes which are difficult to over-
come [7]. Ultra high-throughput sequencing of RNA has
been developed as an approach for transcriptome analy-
sis in several different species and has offered an attrac-
tive approach to measure transcription in a
comprehensive manner. RNA-Seq allows the direct
detection of alternative splicing using the reads mapped
at splice junctions including the novel splicing without
the annotation information. Genome-wide measure-
ments of transcriptomes are increasingly done by RNA-
Seq which provides a far more precise measurement of
expression levels of isoforms than other methods [8].
The rapidly-developing RNA-Seq techniques require
substantial algorithmic advances. Several tools and stra-
tegies have been proposed to deal with the complex
bioinformatics analysis of RNA-Seq [9-12]. Pepke et al.
[13] provided a comprehensive and up-to-data review of
multi-layered analyses of RNA-Seq data. Mortazavi et al.
[10] proposed to quantify the gene level expression of a
transcript as Reads Per Kilobase per Million mapped
reads (RPKM). Further, Jiang and Wong [14] presented
* Correspondence: xzhou@tmhs.org
1Department of Radiology, The Methodist Hospital Research Institute,
Houston, TX 77030, USA
Full list of author information is available at the end of the article
Xia et al. BMC Bioinformatics 2011, 12:162
http://www.biomedcentral.com/1471-2105/12/162
© 2011 Xia et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.a statistical model to describe how the isoform expres-
sion levels were calculated from the number of reads
mapped to the annotated exons of a gene. Meanwhile,
Bohnert et al. [15] also proposed rQuant to determine
the abundances for each annotated isoforms by mini-
mizing the deviation of the observation from the
expected position-wide read coverage. All these methods
assumed that the number and structures of isoforms of
each gene are known from the reference genome. How-
ever, as Jiang and Wong [14] pointed out, the isoform
level annotation is very incomplete due to the complex-
ity of the transcriptome and the limitations of previous
experimental approaches. To address this issue, Trapnell
et al. proposed Cufflinks [16] to identify transcripts as
well as to estimate the expression levels of identified
transcripts from mapped reads without annotation infor-
mation. In essence, Cufflinks constructs a covering rela-
tion on the read alignments from TopHat [12], and find
a minimum path cover on the directed acyclic graph for
the relation based on Dilworth’s Theorem [17] to con-
struct a parsimonious set of transcripts. After that, the
expression levels of those constructed transcripts are
estimated using established known isoform expression
estimation methods [9,14]. Therefore, the construction
of transcripts in Cufflinks is independent of the expres-
sion level estimation. However, the construction of
expressed transcripts and expression level estimation are
highly associated. We argue that the determination of
parsimonious set of expressed transcripts and expression
level estimation should be implemented jointly. Though
Scripture [18] can also detect the novel isoforms, the
issue of parsimonious expressed isoforms is not
addressed. We also notice that Feng et al. proposed Iso-
Infer [19] to identify isoforms using the detected junc-
tions. The candidate isoforms were constructed by
combining the putative exons followed by selecting a
m i n i m u mb e s ts u b s e tf r o ma l lt h ee n u m e r a t e ds u b s e t s
of the candidate isoforms which can explain the obser-
vation best. However, enumerating all possible subsets
of the candidate isoform set with a given size is often
infeasible. IsoInfer decomposes the large putative exon
set into subsets to address this issue which introduces
more parameters.
Here, we put forward NSMAP to infer the structures
of isoforms as well as to estimate the expression levels
simultaneously. First, the exons are constructed based
on the detected splicing junctions from RNA-Seq data
using TopHat. All the possible isoforms are enumerated
by combination of those detected exons. Then NSMAP
is applied to identify the true expressed isoforms from
the large candidate isoform set as well as to estimate the
expression levels with a sparsity control term to restrict
the number of expressed isoforms. The assumption
behind this sparsity term is that only as few isoforms as
possible should be selected to best explain the observed
number of reads falling on each exon of a gene. Finally,
a model selection step is conducted to select the solu-
tion which compromises the fitting of the observation
and the number of expressed isoforms best. In sum-
mary, our algorithm allows for discovering the struc-
tures of the expressed isoforms of a given gene and for
estimating the concentration of each spliced isoform
simultaneously without the annotated isoform informa-
tion, which makes the identification of new, previously
unknown, alternatively spliced isoforms possible. This
study will help RNA-Seq, a next generation sequencing
technology, advance to its full potential in comprehen-
sive transcriptome analysis.
Results
Data set
We test NSMAP on two simulations with simulated
expression levels derived from two publicly available
mouse RNA-Seq as described in [10]. We also apply
NSMAP on three real in-house RNA-Seq data sets of
myelodysplastic syndromes (MDS) transcriptome analy-
sis to identify isoforms including novel ones featured in
MDS disease. MDS are a diverse collection of hematolo-
gical conditions united by ineffective production of mye-
loid blood cells and risk of transformation to acute
myelogenous leukemia whose frequency and incidence
are increasing in the US population [20]. In our applica-
tion, cryopreserved marrow cells and paraffin embedded
marrow clot sections and marrow core biopsies from 2
MDS patients as well as 1 age-matched control sample
are being studied by Dr. Jeff Chang’s lab at the Metho-
dist Hospital. These MDS patients have been thoroughly
evaluated for clinical/morphologic/immunophenotypic
data and characterized clinically by transfusion depen-
dency and pathologically by significant dysplasia,
increased blasts, and immunophenotypic aberrancy. The
control sample are obtained from patients without cyto-
penias (> 60 years old). We specifically selected these
controls to be age-matched for the MDSs population to
control for the possibility of aging-related changes in
the expression profile mRNA of hematopoietic cells.
Then we apply the RNA-Seq protocol to sequence our
samples. We sequenced the two MDS clinical samples
and one normal sample using Illumina Genome Analy-
zer II. There are around 40 million single-end reads
with read length 76 bp for each sample.
Algorithm Summary
NSMAP comprise four consecutive steps, starting with
junction detection and reads mapping using TopHat
[12] and followed by the candidate isoforms construc-
tion, expressed isoform identification and expression
level estimation along whole regularization path and
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whole solution path. Short reads alignment is the first
step in understanding next-generation sequencing data
and many free alignment software packages are available
[21,22]. Here we use TopHat to perform the alignment
task which can detect the junctions and map a massive
amount of reads to the whole genome flexibly and effi-
ciently. The reference genome sequences are down-
loaded from UCSC genome database [23]. After read
alignment, the next step is to generate the candidate iso-
forms according to the alignment and splice junctions
obtained from TopHat.
Candidate isoforms construction
Based on the alignment results and detected junctions
from TopHat, the exons can be constructed from seg-
ments whose two ends have been detected as junction
points. For example, Figure 1(a) mimics a gene with
nine exons constructed from the detected junctions in a
gene region. The isoforms are formed from combination
of those exons. Each rectangle represents an exon and
arrow line indicates that there is a splice junction
detected between the two exons. This can be interpreted
as a directed graph with each exon as nodes. Each can-
didate isoform can be generated by finding a path
between two nodes on this graph. For instance, Figure 1
(b) displays the possible isoforms with exon 1 and 9 as
source and sink respectively. There are total four paths
connecting exon 1 and 9 as indicated in Figure 1.
Isoform Expression level estimation
Given the candidate isoforms constructed from last step,
we need to select the expressed isoforms from this can-
didate set as well as to estimate the express level of
Figure 1 The construction of exons and isoforms from the alignment result of TopHat. (a) 9 exons are constructed from the alignment
result of TopHat where the dotted line means a junction detected by a read and one arrow line represents a detected junction between two
exons; (b) four possible isoforms constructed from source exon 1 to sink exon 9 using path finding algorithms from graph theory where l, x and
j indicate the exon length, the number of reads falling on this exon and the unknown abundance of each isoform, respectively.
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mation framework of Jiang and Wong [14] by incorpor-
ating a sparsity regularization term. For a gene g,
suppose it has m exons with lengths [L = l1,...,lm]a n dn
isoforms with expression F =[ j1,...,jn]. Assuming each
exon can be either included in an isoform or not, we
have a set of observations X = {Xs|s ∈ S},w h e r eS is an
index set of events which we are interested in. Each
observation Xs Î X is a random variable representing
the number of reads falling into a certain region of
interest in gene g. For example, reads falling into certain
exon or exon-exon junction.
The natural statistical model of count data is the Pois-
son distribution. Each Xs Î X follows Poisson distribu-
tion with a parameter l which is the expected count or
the mean parameter of the Poisson distribution. For
instance, the l for the number of reads falling into exon
j is ljN
n  
i=1
cijφi,w h e r eN is the total number of mapped
reads and cij i s1i fi s o f o r mi contained exon j and 0
otherwise. For a exon-exon junction event, the l is
lN
n  
i=1
cijcikφi, where l is the length of the junction region,
j and k are indexes of the two exons involved in the
junction being investigated.
In general, ls is a linear function of j1,j2,..,jn,i . e .
λs =
n  
i=1
asiφi where asi is a known coefficient. The likeli-
hood function is
P({Xs = xs,s ∈ S}| )=
 
s
P(Xs = xs| )
=
 
s
e−λsλ
xs
s
xs!
Maximum likelihood estimation (MLE) method can be
used to estimate F by maximizing above likelihood
function [14]. However, in the work of Jiang and Wong
[14], the structure of individual isoform is fetched from
the reference genome where only a few of isoforms are
known for each gene. In our application, the structures
of expressed isoforms are unknown which need to be
selected from the large candidate isoform set where
each isoform is formed by combination of detected
exons. To do this, the most important prior information
is arguably sparsity; that is, characteristic pattern of each
gene in cells are expressed by very few isoforms, even
though the total number of possible combinations of
exons in a gene can be large. Utilization of this sparsity
information is crucial to the success of finding the most
relevant isoforms which explain the observed reads best,
in the face of “insufficient” data and/or data uncertainty
[24]. To incorporate this sparsity to our model, we pro-
pose a prior Laplace distribution on F as below:
P( ) ∝ e−t| |1
Laplace distribution assigns higher probability at zero
than Gaussian distribution to produce sparser solution
and has been widely used to encode sparseness prior
[25]. Hence we can employ maximum a posteriori
(MAP) instead of maximum likelihood to estimate F:
P( |{Xs = xs,s ∈ S})
∝ P({Xs = xs,s ∈ S}| )P( )
=
 
s
e−λsλ
xs
s
xs!
· e−t| |1
Taking logarithm on the above equation, we get
F( )=
 
s
−λs + xs logλs − log(xs!) − t| |1
Keep in mind that the expression of each isoform can-
not be negative, that is ji ≥ 0( ji ÎF ), F(F)c a nb e
rewritten as:
F( )=
 
s
−λs + xs logλs − log(xs!) − t
n  
i=1
φi
where ji ≥ 0f o ri = 1,...,S and S is the number of
events with which we are interested. Maximizing F(F)
with respect to F is equivalent to minimizing
J( ;t)=
 
s
 
λs − xs logλs
 
+ t
n  
i=1
φi
To that end, the optimization problem is summarized
as:
    = argmin J( ;t)
subject to λs =
n  
i=1
asiφi
φi ≥ 0, i =1 ,...,n
(1)
We call this Nonnegativity and Sparsity constrained
MAP model as NSMAP. Laplace prior distribution has a
L1 norm term to impose the sparsity. In some cases of
our experiment, we find it may not work well in the
identification of the correct expressed isoforms due to
the similarities between the isoforms. The ideal sparsity
constraint is the L0 regularization, defined as the num-
ber of non-zero entries in a vector. Unfortunately, the
computation of L0 regularization is intractable to solve.
L1 norm is popular because of its intrinsic convex prop-
erty. Some recent works suggest that non-convex regu-
larizations such as Lp regularization with 0 < p < 1 have
better performances in parameter selection and sparse
signal construction [26] than L1 regularization. This
inspires us to use a stronger sparsity constraint with Lp,
0< p < 1 norm to solve our problem. We will implement
a simulation study to compare the performances of
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ment, we set p = 0.5. So the objective function is finally
given by:
J( ;t)=
 
s
 
λs − xs logλs
 
+ t|| ||p
= L( ) + tT( )
(2)
where L( ) 
 
s
 
λs − xs logλs
 
and T( )  || ||p.
Then the expression levels of all the candidate iso-
forms can be obtained by optimizing Equation (1) with
ag i v e nt.W h e nt ® +∞,t h es o l u t i o n    equals zero
without expressed isoforms. With the decreasing of t,
some elements of     will be non-zero to become
expressed isoform. So we have to select an optimal t.
Before doing this, we will calculate the solution path
which consists of solutions corresponding to different
values of t. BLasso [27] is adapted to approximate this
solution path efficiently (see Methods).
Model selection from solution path
After getting the solution path which consists of solu-
tions corresponding to different values of t,w eh a v et o
select the best solution (model) from this solution path
which makes a good balance between the number of
expressed isoforms and the fitting function L(   ) in
equation (2). The solution path will first be grouped
into subsets with increasing model size according to the
number of expressed isoforms of each solution (the
number of positive components of    ). Here the model
size means the number of expressed isoforms. Then the
solution with minimal L(   ) in each group is selected as
the best solution for each model size. Starting from
model size 1, we compare the L(   ) of current model
size with the next model size which have one more
expressed isoforms. If L(   ) is significantly improved by
the larger model size, the model with larger model size
will be updated to the current model and compared
with the remaining models with larger model size than
the updated model. Otherwise the solution     corre-
sponding to the current model size is selected as the
final solution. In this way, the solution with smaller
number of expressed isoforms will be selected prefer-
ably. See the Methods for more detail.
Simulation on the whole genome with different Lp norm
in equation (2)
In the absence of RNA-Seq data from samples for which
we have ground truth isoform quantities, we conduct
simulations to validate our method and evaluate its per-
formance in terms of isoform identification and expres-
sion levels estimation with p = 1 and p = 0.5.
We first derive expression level of each isoform from
the mouse brain and liver RNA-Seq data sets described
in [10] using the Poisson model of [14] with the mouse
UCSC Genes as the annotated reference genome data-
base. Those derived expression levels are employed as
the ground truth to perform the following simulations.
Which exon or splice region the read will fall on is
determined by uniformly sampling proportional to the
simulated ground truth RPKM and the same mapped
reads number of each gene in the real data. After uni-
formly sampling and counting reads number, we can
identify isoform structures and their concentrations
from the simulated RNA-Seq reads data and evaluate
the performance of NSMAP with the simulated ground
truth.
We only consider isoforms with expression levels no
less than 1 RPKM as expressed isoforms. In this simula-
tion, constructed isoforms containing more than half of
the total exons are eligible as the candidate isoforms.
The accuracy of NSMAP largely depends on the critical
step of candidate isoform generation. So, we check
whether our candidate isoforms generated from the
exon reads and exon junctions can cover the true
expressed isoforms. From T a b l e1w es e et h a tm o r e
than 96% of expressed isoforms in the two data sets are
included in the candidate isoforms generated by our
strategy which finds paths on a graph constructed from
exons and splice junctions.
We further compute the fraction of isoforms for
which the estimates are significantly consistent with the
simulated ground truth (percent error =
abs(estimation - truth)
truth
 5%). We refer to this statistic
as the positive fraction [9]. Given the positive isoforms
which are within the 5% deviation from the ground
truths, overall specificities of the two simulations are
also calculated by setting the truly expressed isoforms
with RPKM no less than 1 as positive isoforms and the
false reported isoforms by NSMAP and truly expressed
isoforms with RPKM < 1 as negative isoforms.
The results are summarized in Table 2. We can see
that NSMAP achieved near 80% overall positive fraction
in both simulations. And highly expressed isoforms
(with high RPKM) have high positive fraction. While for
isoforms with low RPKM, the accuracy is not very good
because the number of reads falling on this isoform is
small which may not be sufficient to capture the exons
Table 1 The percentage of expressed isoforms with RPKM
≥1 included in the candidate isoform set.
Tissue Total number of
expressed isoforms
Percentage of expressed
isoforms included in
candidate isoforms
Brain 14,154 96.5%
Liver 10,583 96.1%
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enon is consistent with other studies [28] that the esti-
mation on the low abundance isoform is not very
accurate.
Comparing the performances of NSMAP with p =0 . 5
and p = 1, we notice that Lp norm with p = 0.5 provides
better results than p = 1 in the simulations. To explain
this observation, we conduct the following experiment
and give a mathematical interpretation of the two Lp
norms.
Demonstrations of features of Lp norm with p = 0.5 and
p =1
First, we exemplify our observation in the above simula-
tion that Lp norm with p = 0.5 is better than p =1
through a simulation using the structure of gene Eif5a.
I nt h eU C S Cg e n o m ea n n o t a t i o n ,g e n eE i f 5 ah a s1 4
exons and 9 known isoforms. We set both RPKM
expression levels of the fifth and sixth isoforms as 150
because the two isoforms express most from the estima-
tion using the method of [14] on the mouse brain and
liver RNA-Seq data in [10]. The simulation is performed
based on the expression levels and structures of the two
expressed isoforms under the uniform distribution for
reads. Based on the simulation data, total 71 candidate
isoforms is constructed. The indexes of the two truly
expressed isoforms in the candidate set are 7 and 11,
respectively. From the upper row of Figure 2, we can
see that the two expressed isoforms are selected cor-
rectly when p = 1/2, while in the case of p =1 ,a d d i -
tional two false unexpressed isoforms (with indices of 8
and 10) are also selected.
Then, the lower row of Figure 2 shows the mathema-
tical properties of the two norms. L1/2 norm regulariza-
tion has more similar sparsity property with L0 norm
than L1 norm because the points with high probabilities
in the Laplace-like distribution with L1/2 norm are more
focusing around the axes than those in the Laplace dis-
tribution. This means L1/2 norm regularization imposed
stronger sparsity than L1 norm. The simulation depicts
the stronger sparsity constraint by setting p =1 / 2i s
superior to Laplace priori distribution with p = 1 in our
application. In the following experiments, we select the
Lp norm with p = 1/2.
Comparison with IsoInfer on two RNA-Seq data sets of
MDS samples
Here we compare NSMAP with IsoInfer which have
similar ideas in isoform construction from putative
exons and minimum expressed isoform set selection.
However, IsoInfer selects a subset as expressed isoforms
from candidate isoform set by enumerating all the possi-
ble subsets of the candidate isoform set. In NSMAP, the
selection of expressed isoforms is embedded into the
isoform expression level estimation framework by incor-
porating a sparsity control term.
A transcript can be constructed from all the exon-
intron boundaries as well as the transcription start site
(TSS) and poly-A site (PAS) of an isoform. The exon-
intron boundaries can be inferred from RNA-Seq using
alternative splicing detection tool, such as TopHat and
SpliceMap [29]. The TSS and PAS represent the start
and end expressed segments of a transcript, respectively.
Theoretically, any expressed segments can be the TSS
or PAS which will introduce many false short isoforms
to make isoform inference difficult. We prefer to
retrieve the TSS-PAS from the UCSC known isoform
table as the starts and ends of predicted transcripts and
to identify isoforms within the regions of known genes
whose functions and pathways are intensively studied.
IsoInfer (version 0.9.1) and NSMAP will use those TSS-
PAS and the detected junctions using TopHat to infer
the expressed isoforms from RNA-Seq. Because it is
infeasible to validate all the predicted isoforms, we eval-
uate the two methods by comparing their predictions
with UCSC known isoform data set. The performance
of the method is measured by sensitivity and precision.
Here we use hg19 known human isoforms data set
downloaded from UCSC which contains 77,614 tran-
scripts. A known isoform is identified if it is in the pre-
diction result of a method. Sensitivity is defined as the
number of identified isoforms divided by the number of
all known isoforms from UCSC data base. Precision is
defined as the number of identified known isoforms
divided by the number of predicted isoforms by the
method.
Table 2 Positive fraction and specificity of the estimation
results of NSMAP on the two simulated data sets.
Isoform expressions in RPKM
Tissue RPKM [1,10) [10,10
2) [10
2,10
3) [10
3,10
4) Total
Brain p
= 1/2
Number of
isoforms
7,730 5,630 767 27 14,151
Positive
fraction
67.9% 88.2% 95.4% 100.0% 77.5%
Specificity 83.6%
p=1 Positive
fraction
67.8% 87.9% 95.3% 100.0% 77.3%
Specificity 83.3%
Liver p =
1/2
Number of
isoforms
6,470 3,390 661 62 10,583
Positive
fraction
70.0% 89.8% 97.1% 100.0% 78.2%
Specificity 90.3%
p=1 Positive
fraction
69.5% 89.7% 97.1% 100.0% 77.9%
Specificity 89.8%
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well as their performances. Though NSMAP predicted
less known isoforms than IsoInfer, NSMAP achieves
higher precision than IsoInfer. Most of the known iso-
forms which are predicted by both methods are
common. For example, in MDS sample 1, 857 of 1128
known isoforms predicted by IsoInfer are also identified
by NSMAP. This is reasonable because NSMAP and
IsoInfer have similar ideas in isoform construction from
putative exons and minimum expressed isoform set
Figure 2 Simulation experiments with different Lp norm. Upper Row: Solution paths generated by BLasso for NSMAP with different p norm
on the simulated data on the gene Eif5a. The Y-axis is the estimated isoform concentrations ranging [0,300]. The X-axis for two figures in upper
panel is
 
i
|φi|. Lower Row: The probability density functions of Laplace distribution and a Laplace-like distribution with L1/2 norm P(x)∝exp(-||x||
1/2); both of them have unit variances.
Table 3 The performance of IsoInfer and NSMAP on two RNA-Seq data of MDS samples by comparing the results with
the UCSC known isoforms.
Samples MDS 1 MDS 2
#Mapped reads 18,729,721 22,436,651
Methods IsoInfer NSMAP IsoInfer NSMAP
#Predicted isoforms 10,695 9,772 12,466 10,185
#Identified known isoforms 1,128 1,078 1,632 1,469
#Common known isoforms predicted by both methods 857 1103
Sensitivity 1.5% 1.5% 2.1% 2.0%
Precision 10.5% 11.0% 13.1% 14.4%
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predicted by both NSMAP and IsoInfer where the novel
isoform is very consistent with the read coverage from
RNA-seq data.
However, IsoInfer selects a subset as expressed iso-
forms from candidate isoform set by evaluating all the
possible subsets of the candidate isoforms. In NSMAP,
the selection of expressed isoforms is embedded into
the isoform expression level estimation framework by
incorporating a sparsity control term. In this way, the
selection of expressed isoforms is automatic and more
efficient than testing all the possible sub sets of the can-
didate isoforms.
We also notice that more known isoforms are pre-
dicted in MDS sample 2 than MDS sample 1, because
there are more reads are mapped in MDS sample 2.
This observation tells us that deeper sequencing will
improve the performances of IsoInfer and NSMAP.
Here, the sensitivities of the two methods are very
low. The reason is that we compare the predicted iso-
forms with the large UCSC known isoform set. Some of
the UCSC known isoforms may not express in the sam-
ple. So the effective sensitivities will be larger than those
numbers. This comparison against UCSC known iso-
form data set does not mean all the predicted isoforms
without annotation are false. Especially those predicted
novel isoforms with high RPKM are promising to be
true novel isoforms. For example, if we select the pre-
dicted isoforms with expression level larger than 100
R P K M ,i nM D Ss a m p l e1a n d2 ,3 7o u to f6 7a n d5 3
out of 105 predicted isoforms by NSMAP will be anno-
tated in the UCSC known isoforms table. And the lowly
expressed isoforms have higher probability to be false
positive or artifacts due to the insufficient reads for cap-
turing the true structure of an isoform. So we need to
set an expression level threshold to refine the predicted
isoforms. This issue is addressed in the following
section.
Example of identified isoforms using NSMAP and
Expression Level Threshold Selection
Here we exemplify isoforms of a gene TCF20 estimated
by NSMAP. TCF20 encodes protein transcription factor
20 which localizes to the nucleus and displays DNA-
binding and transactivation activities. TCF20 has five
exons and alternative splicing results in two known
transcript variants encoding different isoforms in the
UCSC reference genome (Figure 4(d)). The RNA-Seq
data is first processed by TopHat to detect the splicing
junctions. Figure 4(a) shows the splicing junctions of
TCF20 on MDS sample 1 detected by TopHat. Then
nine exons are constructed based on detected junctions
in Figure 4(b). NSMAP predicts three isoforms with
expression level 0.1, 3.0 and 3.5 respectively (Figure 4
(c)). Compared with the annotated isoforms of TCF20
(Figure 4(d)), we confirm that the top two highly
expressed predictions are the same with the annotations.
This example demonstrates the ability of NSMAP in iso-
form identification.
However, NSMAP still predicts an additional lowly
expressed isoform (0.1 RPKM) which is not annotated
in the UCSC known isoform. Higher expression level of
an isoform means more reads will be sampled from this
isoform to capture the structure of this isoform. So the
predicted isoforms with low expression levels have more
probability to be artifacts. We need an expression level
threshold T to exclude those lowly expressed isoforms.
The selection of T is a trade-off between sensitivity and
specificity. The smaller the value T is, the higher sensi-
tivity but lower specificity the result will achieve.
Because there is no ground truth for the predicted novel
isoforms, we set the predicted isoforms which are anno-
tated by the UCSC known isoforms as positive, others
as negative. To determine this value, we explore the
ROC curve of the prediction result of MDS sample 1
where the TCF20 in Figure 4 comes from. The ROC
curve and selected threshold of the prediction result of
Figure 3 The prediction results of NSMAP and IsoInfer on a genome region based on MDS sample 1. (a)Detected Junctions using
TopHat; (b) Read coverage of the real data on this region (chr13:29233240-29253091); (c) Two isoforms predicted by NSMAP and IsoInfer. One is
novel and another one is annotated by UCSC known isoforms (d) The known isoform (gene POMP) on this region.
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Page 8 of 13NSMAP on the MDS sample 1 are depicted in Figure 5.
The optimal threshold T in this ROC curve is 1.216.
The intuition of this optimal threshold is that at this
point, the increase rate of sensitivity equals to the
increase rate of (1-Specificity). When the threshold is
infinite, both sensitivity and (1- Specificity) are 0. With
the decrease of threshold T, both sensitivity and (1-spe-
cificity) will increase. But the increase rate of sensitivity
is larger than that of (1-specificity) until T reduces to
the point 1.216. After that point, the increase rate of (1-
specificity) will be larger than sensitivity. (1-specificity)
actually is the false positive rate. We prefer higher sensi-
tivity and lower false positive rate. So we select this
point as the optimal point.
In the predicted isoforms of gene TCF20 in Figure 4,
the two annotated isoforms have expression levels 3.0
and 3.5, respectively, which are above the selected
threshold T = 1.216. While the expression level of the
un-annotated isoform is 0.1 which is obviously under
this threshold. In this way, we perform a further refine-
ment of the prediction result. In the following real data
analysis, we only consider NSMAP predicted isoforms
which are larger than the optimal expression level
threshold in each sample.
Clinical MDS sequencing data analysis
The goal is to use our NSMAP to identify known and
n o v e li s o f o r m sw h i c hm a yb er e l a t e dw i t hM D S .W e
a p p l yN S M A Po nt h ea l i g n m e n tr e s u l t so ft h et h r e e
data sets from TopHat to identify the expressed iso-
forms and their expression levels. The predicted
Figure 4 Take gene TCF20 as an example to demonstrate the procedure and prediction result of NSMAP. (a)The region of gene TCF20
and the detected splicing junctions using Tophat. (b) The constructed exons based on the detected splicing junctions for gene TCF20. The
number in the parentheses of the each left label is the number of reads falling on the corresponding exon. (c) NSMAP predicts three isoforms
for TCF20 with expression levels in the parentheses. (d) The two annotated isoforms of gene TCF20 in the UCSC reference genome.
Figure 5 ROC curve of the prediction of NSMAP on MDS
sample 1 and the selected expression level threshold.
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Page 9 of 13isoforms are compared with the UCSC annotated refer-
ence genes to distinguish the known and novel isoforms.
For the known isoforms, we select the differentially
expressed isoforms with fold change greater than 2 on
both disease samples compared with the control sample.
We also select MDS featured novel isoforms which are
detected in both MDS samples but are absent in the
normal sample. Finally, we get total 785 differentially
expressed known isoforms and 128 novel isoforms with
RPKM over 5. The two selected isoform sets were fed
into Ingenuity Pathways Analysis (IPA) [30] respectively.
IPA is a database search tool for finding function and
pathway for specific biological states. Here we used IPA
to explore the pathways enriched in the two selected
isoform sets. The top 4 enriched canonical pathways of
the two analyses are listed in Table 4 where mitochon-
drial dysfunction is both enriched in the known and
novel differentially expressed isoform sets which is
known to closely related with MDS [31]. The Oxidative
phosphorylation and mitochondrial dysfunction are
enriched by both differentially expressed isoform sets
which mean the novel differentially expressed isoforms
have similar biological functions with the differentially
expressed known isoforms. That observation indicates
the prediction of novel isoforms is consistent with the
known isoforms.
Discussion
Through simulations that closely modelled real data, we
confirm our method’s effectiveness for experiments in
both mouse brain and liver RNA-Seq data. We also com-
pare NSMAP with IsoInfer to show that NSMAP has
comparable performance in identifying known isoforms
from RNA-Seq reads. Finally, we apply NSMAP on our
MDS RNA-Seq data analysis and find some differentially
expressed known isoforms and novel isoform candidates
which involve in some MDS related pathways.
Recently, Lacroix et al. [32] showed that unique solu-
tion cannot be guaranteed theoretically in isoform iden-
tification from short sequence reads. For example, in
our case, all possible transcript isoforms are enumerated
according to the detected junction reads. Among these
isoforms, one truly expressed isoform may be linear
combinations of the other isoforms in terms of exon
arrangements. Then the solution of this case is not
unique. The assumption of NSMAP to address this
issue is that the solution which employs as few
expressed isoforms as possible to explain the most
observation is preferred. Though this assumption is
identical to the assumption made by Cufflinks, the
implementation of this assumption in NSMAP is totally
different from Cufflinks. Cufflinks constructed a parsi-
monious set of transcripts followed by the expression
level estimations of those constructed transcripts using
established expression level estimation model. However,
NSMAP enumerates all the possible isoforms formed by
the combinations of identified putative exons from
TopHat and incorporates a prior distribution into the
expression level estimation model to control the number
of expressed isoforms. That means the identification of
expressed isoforms and the expression level estimations
of those identified isoforms are done jointly in NSMAP.
Paired-end sequencing can dramatically improve the
accuracy of isoform level expression estimation which is
becoming ubiquitous. Recently, Salzman et al. [33] pro-
posed “insert length model” to extend Jiang and Wong’s
single-end sequencing work [14] to paired-end sequen-
cing analysis by modeling the insert length distribution.
So we can use this idea to handle paired-end sequencing
data in our current framework.
Paired-end sequencing can dramatically improve the
accuracy of isoform level expression estimation which is
becoming ubiquitous. In paired end sequencing, only
the fragments in a specified range will be selected. Sev-
eral papers have used this information by modeling the
fragment length distribution to improve isoform decon-
volution problem [16,34]. Salzman et al. [33] proposed
“insert length model” to extend Jiang and Wong’ss i n -
gle-end sequencing work [14] to paired-end sequencing
analysis by modeling the fragment length distribution.
So we can use this idea to handle paired-end sequencing
data in our current framework. In paired-end sequen-
cing, Salzman et al. defines asi = q(fsi)N for an event s
where the mate reads are mapped into two specified
positions on genome. Here fsi is the length of corre-
sponding fragment on the i-th transcript and q(f)i st h e
probability of observing a fragment with length f.I n
practice, q(f) can be approximated by the empirical
probability mass function computed from all the
mapped paired-end reads. In order to reduce the num-
ber of events, the minimal sufficient statistics is used to
group the events into minimal categories for computa-
tional purpose. In this way, we can incorporate the
paired-end information into our model by redefining asi
to address paired-end sequencing data.
Currently, NSMAP uses the TSS and PAS retrieved
from UCSC known isoforms. We will extend it to
Table 4 The top 4 enriched canonical pathways from
Ingenuity Pathways Analysis of the differentially
expressed known isoforms and novel isoforms.
Differentially Expressed known
isoforms
Differentially expressed novel
isoforms
Granzyme A signalling Mitochondrial dysfunction
Oxidative phosphorylation Oxidative phosphorylation
Mitochondrial dysfunction Methane metabolism
cAMP-mediated signaling Protein ubiquitination pathway
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Page 10 of 13identify TSS and PAS from RNA-seq by the following
scheme. If the start point of a putative exon is not a
junction point, this putative exon can be regarded as
TSS. And if the end point of a putative exon is not a
junction point, this putative exon can be regarded as
PAS. Here junction point means this point is the start
or end of a splicing junction.
As our primary motivation is to design a method to
identify the isoform structure without annotated refer-
ence isoform genome, the usefulness of NSMAP is lar-
gely dependent on the expression levels of true isoforms
and splicing junction detection. We believe that the
accuracy of this approach will increase significantly as
the sequencing technology evolves such as paired-end
sequencing technique and generates longer sequences
with less noise and higher throughput.
Conclusions
In this paper, we propose a statistical model NSMAP for
RNA-Seq data analysis which can be used to identify
and quantify isoforms simultaneously without isoform
annotations from reference genome.
Methods
Implementation
We must select a particular value of t at which the esti-
mation is optimal. Before that, the solutions correspond-
ing to different values of t should be calculated. Efron et
al. [35] proposed an efficient algorithm LARS to deter-
mine the exact piecewise linear coefficient paths for the
lasso. Unlike lasso, the path of our solution is not piece-
wise linear. To address this non-piecewise solution
issue, we modify the BLasso[ 2 7 ]t og e tt h es o l u t i o n s
corresponding to different t. The basic ideal of BLasso is
to correct the forward stage-wise boosting algorithm by
allowing backward steps whenever a stop in forward
stage-wise boosting fitting deviates from that of the
lasso.
Optimization: Generalized BLasso for NSMAP:
￿ Step 1(Initialization) Given a small step-size con-
stant ε > 0 and a small tolerance parameter ξ ≥ 0,
take an initial forward step on L(F
(0))i ne q u a t i o n
(2). We define F
(0)≜m1j.
(ˆ j, ˆ m) = argmin
m=ε,j
L(m1j)
Herein ˆ m = ε because of the non-negative constraint
and 1j is a n-dimensional standard basis vector with
all 0’s except for a 1 in the j th entry. So    (0) = ˆ m1ˆ j
where L(F) is defined in equation (2). Then calculate
the initial regularization parameter
t(0) =
L(0) − L(   (0))
T(   (0)) − T(0)
We use IA to represent the active index set. Set the
initial active set I0
A = {ˆ j} and k =0 .
￿ Step 2 (Steepest descent step). Find the steepest
coordinate descent direction on J(F;t)i ne q u a t i o n
(2):
(ˆ j, ˆ m) = arg min ⎧
⎨
⎩
m = ±ε,i fj ∈ Ik
A
m = ε,i f j / ∈ Ik
A
J(    + m1j;t(k))
Take the step if it leads to a decrease of moderate
size ξ in the objective function J(F;t):
If J(   (k) + ˆ m1ˆ j;t(k)) − J(   (k);t(k)) < −ξ
then    (k+1) =    (k) + ˆ m1ˆ j, t(k+1) = t(k)
Otherwise, adjust     to minimize L(F)i ne q u a t i o n
(2) and recalculate the regularization parameter t:
(ˆ j, ˆ m) = arg min ⎧
⎨
⎩
m = ±ε,i f j ∈ Ik
A
m = ε,i f j / ∈ Ik
A
L(   (k) + m1j),
   (k+1) =    (k) + ˆ m1ˆ j,
t(k+1) = min
 
t(k),
L(   (k)) − L(   (k+1))
T(   (k+1)) − T(   (k))
 
.
Update Ik+1
A whose elements are the indexes of the
positive entries of    (k+1).
￿ Step 3 (iteration). Increase k by one and repeat
Step 2 until t
(k) ≤ 0.
Computationally, BLasso takes roughly O(1/ε)s t e p st o
produce the whole path [27]. The actual computation
complexity depends on the actual objective function and
minimization method used in each step when calculat-
ing (ˆ j, ˆ m). In the following experiments, Î is set as 0.1
and ξ =1 e - 10.
Model selection and expression level estimation
A sequence of solutions {   (k)|k =0 ,1 ,...,K} corre-
sponded to the decreasing t during iterations where K is
the number of iterations. Each regularization parameter
t
(k) has a solution with several isoforms Ik
A selected as
active. There is only one selected isoform in I0
A when t is
on its largest value t
(0).W i t ht h ed e c r e a s i n go ft,m o r e
isoforms are selected into the active set and the number
o fe x p r e s s e di s o f o r m sv a r i e sa ss h o w ni nF i g u r e6 .W e
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Page 11 of 13should select the best model from these solutions which
can explain as more observations as possible using as few
expressed isoforms as possible. The number of expressed
isoforms of a solution equals with the number of positive
elements in    (k). In order to control the model size, we
group the sequential solutions {   (k)|k =0 ,1 ,...,K} into
Hh = {   (k)|C(   (k)) = h,k =0 ,1 ,...,K} according to the
number of positive elements in each solution    (k),w h e r e
C(   (k)) is used to count the number of positive elements
in solution    (k) and Hh is a subset of
{   (k)|k =0 ,1 ,...,K}. The number of expressed isoforms
of each solution in Hh equals h.
We first select the best solution within each group Hh.
Because the model size within each group is the same,
the solution    (k) whose L(   (k)) is minimal in group Hh
is selected as the best solution in this group.
Those best solutions    
(k)
h in each group are put into a
set {   
(k)
1 ,   
(k)
2 ,   
(k)
3 ,...,   
(k)
M } ordered by the increasing
number of expressed isoforms where M is the largest
number of expressed isoforms in the solution path and
   
(k)
1 has one expressed isoform which is the best solution
among the solutions with one expressed isoform. The final
best solution is selected from {   
(k)
1 ,   
(k)
2 ,   
(k)
3 ,...,   
(k)
M }
by likelihood ratio test (LRT) [36].
Starting from the sparsest solution    
(k)
1 with one iso-
form, we compare    
(k)
1 with solution    
(k)
2 which has two
expressed isoforms to determine which solution is better
and should thus be preferred using LRT by deriving the
p-value of the obtained difference between L(   
(k)
1 ) and
L(   
(k)
2 ). The test statistic of this difference is defined as
D = −2log
L(   
(k)
1 )
L(   
(k)
2 )
. In most cases, the probability distri-
bution of this test statistic D can be approximated by a
chi-square distribution with  = df(A)-df(B) degrees of
freedom, where df(A) and df(B) are the degrees of free-
dom of models A and B respectively. That means D ~
c
2( ). In our case, the difference between the degrees
of freedom of the two models are (df(A) - df(B)) = (2-1)
= 1 and the p-value of D can be calculated according to
D ~ c
2(1 ). If prob(D)>0 . 0 1w h i c hm e a n sL(   
(k)
2 ) is
not significantly smaller than L(   
(k)
1 ), we select    
(k)
1 as
our final best solution and stopped the searching.
Otherwise,    
(k)
2 and    
(k)
3 are compared using LRT alike,
and so on. The whole flowchart on model selection is
summarized in Figure 7.
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